Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard Health Care ETF (NY:VHT)

279.41 -2.58 (-0.91%)
Streaming Delayed Price Updated: 11:13 AM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard Health Care ETF

< Previous 1 2 3 4 5 Next >
News headline image
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy? ↗
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals. 
Via The Motley Fool
Topics ETFs
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year. 
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? ↗
Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact. 
Via The Motley Fool
Topics ETFs
News headline image
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ ↗
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S.... 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare. 
Via The Motley Fool
Topics ETFs
News headline image
3 ETFs That Historically Perform Well in the Final Weeks of May ↗
May's reputation isn't as bad as some investors think, and this mix of ETFs can get the job done as summer nears. 
Via The Motley Fool
Topics ETFs
News headline image
Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗
It's tough to think of an industry with more staying power than healthcare. 
Via The Motley Fool
Topics ETFs Retirement
News headline image
3 Vanguard ETFs to Buy to Protect Your Portfolio From a Potential Stock Market Crash ↗
There are enough economic signals to think that a bear market could be a real risk, so it's time to think about ways to protect yourself. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Should You Really Buy Stocks With the S&P 500 Near Its Record High? Historical Data Gives a Clear Answer. ↗
Avoiding the stock market at all-time highs has historically been a mistake. 
Via The Motley Fool
Topics Bonds Economy Stocks
News headline image
1 No-Brainer Healthcare Vanguard ETF to Buy Right Now for Less Than $1,000 ↗
Healthcare stocks have been laggards for a while now. The current economic slowdown and structural tailwinds make it much more attractive now. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
3 ETFs to Own if the U.S. Economy Slows in 2026 ↗
The U.S. economy is showing signs of slowing and recession risk is rising. Here's how to prepare your portfolio. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
Want to Buy the Dip on Eli Lilly? Consider This Low-Cost Vanguard ETF ↗
After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026. 
Via The Motley Fool
Topics ETFs
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism ↗
In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six... 
Via Stocktwits
News headline image
TLRY Stock Slumps 4%: What’s Driving The Selloff? ↗
Tilray said that it has acquired the BrewDog brand and related intellectual property, UK brewing operations and eleven strategic brewpubs in the United Kingdom and Ireland. 
Via Stocktwits
Topics Cannabis Intellectual Property
News headline image
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue ↗
The company generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
PRCT Stock Tumbles Pre-Market: BofA Questions Earnings Visibility, Cuts Target To $20 ↗
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
XWEL Stock Soars 300%, Hits 200-DMA For First Time In Nearly Four Months – What Triggered The Rally? ↗
The company signed a securities purchase agreement with American Ventures on Tuesday as part of a private placement worth up to $31.3 million. 
Via Stocktwits
News headline image
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? ↗
CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market. 
Via Stocktwits
News headline image
Why Did IXHL Stock Tank Over 32% Today? ↗
The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 
Via Stocktwits
News headline image
EVH Stock On Track To Open At Record Low – Here’s Why Keybanc Turned Cautious ↗
KeyBanc downgraded Evolent Health to ‘Sector Weight’ from ‘Overweight’, citing a lack of visibility in near-term EBITDA recovery. 
Via Stocktwits
News headline image
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? ↗
The FDA has granted Breakthrough Therapy Designation to Larimar’s frataxin protein replacement therapy, nomlabofusp. 
Via Stocktwits
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, lifileucel and reported strong fourth-quarter earnings. 
Via Stocktwits
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
Via Stocktwits
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗
Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 
Via Stocktwits
Topics Intellectual Property
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks. 
Via Stocktwits
News headline image
Why Did INTS Stock Plummet 30% Pre-Market Today? ↗
Intensity Therapeutics announced a 1-for-25 reverse stock split, consolidating every 25 existing shares into a single new share. 
Via Stocktwits
News headline image
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results ↗
Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin. 
Via Stocktwits
News headline image
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
Via Stocktwits
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.